The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat

Journal of Bone and Mineral Research

Volumn 26, Issue 11, 2011, Pages 2672-2681

  Moe, Sharon M ^a,b   Radcliffe, J Scott ^c   White, Kenneth E ^a   Gattone II, Vincent H ^a   Seifert, Mark F ^a   Chen, Xianming ^a   Aldridge, Blaire ^c   Chen, Neal X ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Bone; CKD MBD; FGF23; Intestine; Kidney; Mineral; Parathyroid hormone; Phosphorus

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MESSENGER RNA; PARATHYROID HORMONE; SEVELAMER CARBONATE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE STRENGTH; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; CONTROLLED STUDY; DISEASE COURSE; FEMUR NECK; HISTOPATHOLOGY; ILEUM; JEJUNUM; KIDNEY FUNCTION; MALE; MINERAL DEFICIENCY; NONHUMAN; OSTEOCLAST; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE TRANSPORT; PROTEIN EXPRESSION; RAT;

ANIMALS; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; CALCIUM CARBONATE; GENE EXPRESSION REGULATION; KIDNEY FAILURE, CHRONIC; MALE; ORGAN SPECIFICITY; POLYAMINES; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80055024312     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.485     Document Type: Article

References (42)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G,. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69 (11): 1945-53. (Pubitemid 43924257)
2. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd., A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009; 75 (2): 176-84.
3. Moe SM, Sprague S,. Mineral bone disorders in chronic kidney disease. In:, Brenner B, ed. The kidney 8th ed, vol 2 Philadelphia: Saunders; 2008, pp 1784-813.
4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL,., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71 (1): 31-8. (Pubitemid 44967731)
5. Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H,. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone. 2009; 44 (4): 678-83.
6. K/DOQI NKF. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Supplement): S1-S201.
7. KDIGO. Clinical practice guidelines for the management of CKD-MBD. Kidney Int. 2009; 76 (S113): S1-S130.
8. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, Gattone VH 2nd., R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant. 2009; 24 (8): 2371-7.
9. Kaspareit-Rittinghausen J, Deerberg F, Wcislo A,. Hereditary polycystic kidney disease. Adult polycystic kidney disease associated with renal hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats. Am J Pathol. 1991; 139 (3): 693-6.
10. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd., Autosomal-dominant polycystic kidney disease in the rat. Kidney Int. 1993; 43 (3): 522-34. (Pubitemid 23071934)
11. Kaspareit-Rittinghausen J, Deerberg F, Rapp KG, Wcislo A,. A new rat model for polycystic kidney disease of humans. Transplant Proc. 1990; 22 (6): 2582-3.
12. Cowley BD Jr, Grantham JJ, Muessel MJ, Kraybill AL, Gattone VH 2nd., Modification of disease progression in rats with inherited polycystic kidney disease. Am J Kidney Dis. 1996; 27 (6): 865-79. (Pubitemid 26169040)
13. Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH 2nd., Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis. 1997; 29 (2): 265-72. (Pubitemid 27130738)
14. Fleet JC, Wood RJ,. Specific 1,25(OH)2D3-mediated regulation of transcellular calcium transport in Caco-2 cells. Am J Physiol. 1999; 276 (4 Pt 1): G958-64. (Pubitemid 29214110)
15. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25 (4): 402-8. (Pubitemid 34164012)
16. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, Waage A,. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res. 1999; 14 (2): 256-63. (Pubitemid 29066251)
17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR,. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
18. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E,. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 2003; 64 (5): 1653-61. (Pubitemid 37323693)
19. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M,. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006; 69 (3): 531-7. (Pubitemid 43164446)
20. Yokozawa T, Zheng PD, Oura H, Koizumi F,. Animal model of adenine-induced chronic renal failure in rats. Nephron. 1986; 44 (3): 230-4. (Pubitemid 16002549)
21. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC,. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009; 75 (6): 617-25.
22. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M,. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol Dial Transplant. 2006; 21 (3): 634-43. (Pubitemid 43372908)
23. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM,. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol. 2010; 5 (2): 286-91.
24. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W,. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009; 4 (1): 178-85.
25. Peerce BE, Weaver L, Clarke RD,. Effect of 2'-phosphophloretin on renal function in chronic renal failure rats. Am J Physiol Renal Physiol. 2004; 287 (1): F48-56. (Pubitemid 38780582)
26. Marks J, Churchill LJ, Srai SK, Biber J, Murer H, Jaeger P, Debnam ES, Unwin RJ,. Intestinal phosphate absorption in a model of chronic renal failure. Kidney Int. 2007; 72 (2): 166-73. (Pubitemid 47067387)
27. Loghman-Adham M,. Renal and intestinal Pi transport adaptation to low phosphorus diet in uremic rats. J Am Soc Nephrol. 1993; 3 (12): 1930-7.
28. Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H,. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial. 2005; 9 (4): 331-5. (Pubitemid 41800804)
29. Marks J, Churchill LJ, Debnam ES, Unwin RJ,. Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol. 2008; 19 (12): 2313-20.
30. Marks J, Debnam ES, Unwin RJ,. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol. 2010; 299 (2): F285-96.
31. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T,. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009; 111 (4): p59-66.
32. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K,. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009; 45 (6): 1161-8.
33. Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S,. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol. 2010; 299 (5): F1212-7.
34. Yamamoto R, Minamizaki T, Yoshiko Y, Yoshioka H, Tanne K, Aubin JE, Maeda N,. 1alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro. J Endocrinol. 2010; 206 (3): 279-86.
35. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T,. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299 (4): F882-9.
36. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N,. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005; 280 (4): 2543-9. (Pubitemid 40189356)
37. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T,. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19 (3): 429-35. (Pubitemid 38787398)
38. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J,. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117 (12): 4003-8. (Pubitemid 350224109)
39. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N,. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998; 53 (2): 448-53. (Pubitemid 28097862)
40. Jokihaara J, Porsti I, Pajamaki I, Vuohelainen T, Jolma P, Koobi P, Kalliovalkama J, Niemela O, Kannus P, Sievanen H, Jarvinen TL,. Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. J Bone Miner Res. 2006; 21 (5): 745-51.
41. Nickolas TL, Leonard MB, Shane E,. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74 (6): 721-31.
42. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y,. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003; 17 (12): 2393-403. (Pubitemid 37542205)